Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 13-24 , February 2009

What have we learnt about the development and progression of early RA from RCTs?

  • David L. Scott, BSc, MD, FRCP (Professor of Clinical Rheumatology)

      Affiliations

    • Corresponding Author InformationTel.: +44 207 848 5215; Fax: +44 207 848 5202.

References 

  1. Dwosh IL, Stein HB, Urowitz MB, et al. Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum. 1977;20:685–692
  2. Mäkisara P, Nissilä M, Kajander A, et al. Comparison of penicillamine and gold treatment in early rheumatoid arthritis. Scand J Rheumatol. 1978;7:166–170
  3. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?. Rheumatology. 2001;40:1211–1220
  4. Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology. 2005;44:1414–1421
  5. Quinn MA, Cox S. The evidence for early intervention. Rheum Dis Clin North Am. 2005;31:575–589
  6. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55:864–872
  7. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34–45
  8. Meyer O, de Bandt M, Berthelot JM, et al., Working Group for Therapeutic Strategies for Rheumatoid Arthritis  Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. Joint Bone Spine. 2007;74:73–78
  9. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;1:CD006356
  10. Du Pan SM, Gabay C, Finckh A. A systematic review of infliximab in the treatment of early rheumatoid arthritis. Ther Clin Risk Manag. 2007;3:905–911
  11. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124–134
  12. Borg G, Allander E, Lund B, et al. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2 year double-blind, placebo controlled study. J Rheumatol. 1988;15:1747–1754
  13. The Australian Multicentre Clinical Trial Group . Sulfasalazine in early RA. J Rheumatol. 1992;19:1672–1677
  14. Hannonen P, Mottenen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48 week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 1993;36:1501–1509
  15. Choy EH, Scott DL, Kingsley GH, et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol. 2002;20:351–358
  16. Davis MJ, Dawes PT, Fowler PD, et al. Should disease modifying drugs be used in mild rheumatoid arthritis?. Br J Rheumatol. 1991;30:451–454
  17. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med. 1993;119:1067–1071
  18. The HERA study group . A randomised trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am J Med. 1995;98:156–168
  19. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1–12
  20. Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 2006;54:1422–1428
  21. Stein CM, Pincus T. Placebo-controlled studies in rheumatoid arthritis: ethical issues. Lancet. 1999;353:400–403
  22. Buckland-Wright JC, Clarke GS, Chikanza IC, Grahame R. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol. 1993;20:243–247
  23. Egsmose C, Lund B, Borg G, et al. Patients with early arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol. 1995;22:2208–2213
  24. Van der Heide A, Jacobs JWG, Bijlsma JWJ, et al. The effectiveness of early treatment with ‘second-line’ anti-rheumatic drugs. A randomized controlled trial. Ann Intern Med. 1996;124:699–707
  25. Munro R, Hampson R, McEntergart A, et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis. 1998;57:88–93
  26. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001 Oct 15;111(6):446–451
  27. Verstappen SM, Jacobs JW, Bijlsma JW, et al., Utrecht Arthritis Cohort Study Group  Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum. 2003;48:1797–1807
  28. Nuver-Zwart IH, Van Riel PLCM, Van de Putte LBA, Gribnau FWJ. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis. 1989;48:389–395
  29. Van der Heijde DM, Van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036–1038
  30. Peltomaa R, Paimela L, Helve T, Leirisalo-Repo M. Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study. Scand J Rheumatol. 1995;24:330–335
  31. Menninger H, Herborn G, Sander O, et al. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol. 1998;37:1060–1068
  32. Rau R, Herborn G, Karger T, et al. Progression in early erosive rheumatoid arthritis: 12 month results from a randomised controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol. 1998;37:1220–1226
  33. Zeidler HK, Kvien TK, Hannonen P, et al. Progression of joint damage in early active severe rheumatoid arthritis during eighteen months of treatment: comparison of low dose cyclosporin and parenteral gold. Br J Rheumatol. 1998;37:874–882
  34. Stenger AAME, Van Leuewen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol. 1998;37:1157–1163
  35. Van Jaarsveld CHM, Jacobs JWG, van der Veen MJ, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis. 2000;59:468–477
  36. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443–1449
  37. Haagsma C, van Riel P, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36:1082–1088
  38. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–225
  39. Gerards AH, Landewe RB, Prins AP, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis. Ann Rheum Dis. 2003;62:291–296
  40. Marchesoni A, Battafarano N, Arreghini M, et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology. 2003;42:1545–1549
  41. Miranda JM, Alvarez-Nemegyei J, Saavedra MA, et al. (GRECIA Group). A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res. 2004;35:36–42
  42. Sarzi-Puttini P, D'Ingianna E, Fumagalli M, et al. An open, randomized comparison study of cyclosporine A, cyclosporine A+methotrexate and cyclosporine A+hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int. 2005;25:15–22
  43. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333:142–146
  44. Proudman SM, Conaghan PG, Richardson C, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum. 2000;43:1809–1819
  45. Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004;63:797–803
  46. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52:3360–3370
  47. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. Arthritis Rheum. 2005;52:3371–3380
  48. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis. Arthritis Rheum. 2006;54:1401–1409
  49. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004;63:149–155
  50. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–3443
  51. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 2004;50:1107–1116
  52. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis Rheum. 2005;52:27–35
  53. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37
  54. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–382
  55. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and suphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309–318
  56. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568–1573
  57. Choy EH, Smith CM, Farewell V, et al., CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group  Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis. 2008;67:656–663
  58. van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol. 1998;25:1493–1498
  59. Ferraccioli GF, Gremese E, Tomietto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A,sulphasalazine) or monotherapy for three years. Rheumatology. 2002;41:892–898
  60. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–269
  61. Capell HA, Madhok R, Porter DR, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 2007;66:235–241
  62. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146:406–415
  63. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58:1310–1317
  64. van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination therapy in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis. 2008;67:1574–1577

PII: S1521-6942(08)00158-7

doi: 10.1016/j.berh.2008.12.009

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 13-24 , February 2009

Article Tools

* Image Usage & Resolution